Zydus Lifesciences profit and loss

Latest FY26

Revenue: ₹27,148cr+16.8% on FY25
EBITDA: ₹8,475cr+20.1% on FY25
Net profit: ₹5,124cr+9.6% on FY25
EPS: ₹50.09+11.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	28,592	27,148	23,242	19,547	17,237	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	461	510	270	284	187
	29,052	27,658	23,511	19,832	17,424
	5,142	5,110	4,373	4,581	4,123
	3,702	3,071	2,150	1,898	1,949
	−1,101	−888	−185	−250	238
	4,781	4,418	3,681	3,138	2,766
	510	439	166	81.2	130
	1,725	1,408	916	764	723
	7,752	6,963	6,164	4,797	4,302
	22,511	20,520	17,265	15,008	14,230
	8,316	8,475	7,059	5,384	3,860
	6,591	7,067	6,143	4,620	3,137
Profit
	6,542	7,138	6,246	4,823	3,194
	−535	−517	−220	−14.2	−604
	6,007	6,621	6,027	4,809	2,590
	1,525	1,380	2,049	1,493	690
	−9.8	215	−637	−515	−103
	1,515	1,595	1,412	978	588
	101	97.1	57.8	118	94.6
	4,593	5,124	4,673	3,973	2,092
	4,492	5,026	4,615	3,831	2,002
	0.0	0.0	0.0	23.0	−4.6
	−812	−775	−100	−200	−314
	3,781	4,349	4,573	3,773	1,778
	4,513	5,040	147	113	1,960
	79.7	83.5	4,526	3,860	132
Per share
	₹44.87	₹50.09	₹44.97	₹38.14	₹19.30
	₹44.87	₹50.09	₹44.97	₹38.14	₹19.30
Continuing & discontinued operations
	0.0	0.0	0.0	29.2	−7.0
	0.0	0.0	0.0	6.2	−2.4
Other comprehensive income — detail
	−812	−775	−100	—	—
	−3.5	−32.9	−0.5	−54.3	−16.0
	16.0	13.5	0.0	—	—
	—	—	—	−6.1	0.3
	−793	−728	−99.5	−152	−298
	3,708	4,267	147	3,659	1,646
	72.9	81.4	4,426	113	132
Per share — as-filed variants
	₹44.87	₹50.09	₹44.97	₹37.91	₹19.35
	₹44.87	₹50.09	₹44.97	₹37.91	₹19.35
	₹0.00	₹0.00	₹0.00	₹0.23	−₹0.05
	₹0.00	₹0.00	₹0.00	₹0.23	−₹0.05
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	20,849	19,856	16,904	13,319	10,927
	72.9%	73.1%	72.7%	68.1%	63.4%
Adjusted (ex-exceptional items) — derived
	6,542	7,138	6,246	4,823	3,194
	−535	−517	−220	−14.2	−604
	4,993	5,516	4,841	3,984	2,559
	₹48.78	₹53.92	₹46.59	₹38.25	₹23.61

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZYDUSLIFE₹1,175.50

Zydus Lifesciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA DRREDDY CIPLA TORNTPHARM DIVISLAB MAXHEALTH APOLLOHOSP AUROPHARMAMcap ₹1.18L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	17,237.4	19,547.4	23,241.5	27,148.4	28,591.7
Other Income	186.6	284.1	269.5	509.5	460.7
Total Income	17,424.0	19,831.5	23,511.0	27,657.9	29,052.4
Expenses
+ Cost of Materials Consumed	4,122.6	4,580.5	4,372.9	5,109.6	5,141.9
+ Purchases of Stock-in-Trade	1,949.4	1,897.9	2,150.0	3,070.5	3,701.5
+ Changes in Inventories	238.1	-250.2	-184.9	-887.5	-1,100.5
+ Employee Benefit Expense	2,765.6	3,137.6	3,680.6	4,417.9	4,780.9
+ Finance Costs	129.9	81.2	165.9	438.9	510.2
+ Depreciation & Amortisation	722.7	764.1	915.8	1,408.0	1,724.6
+ Other Expenses	4,301.8	4,797.3	6,164.4	6,962.8	7,751.9
Total Expenses	14,230.1	15,008.4	17,264.7	20,520.2	22,510.5
EBITDA	3,859.9	5,384.3	7,058.5	8,475.1	8,316.0
EBIT	3,137.2	4,620.2	6,142.7	7,067.1	6,591.4
Profit
PBT before Exceptional Items	3,193.9	4,823.1	6,246.3	7,137.7	6,541.9
+ Exceptional Items	-604.2	-14.2	-219.6	-516.6	-534.8
Pretax Income	2,589.7	4,808.9	6,026.7	6,621.1	6,007.1
+ Current Tax	690.4	1,492.6	2,049.3	1,379.5	1,524.7
+ Deferred Tax	-102.6	-515.1	-637.4	215.2	-9.8
Tax Expense	587.8	977.5	1,411.9	1,594.7	1,514.9
+ Share of Associates & JVs	94.6	118.4	57.8	97.1	100.5
Net Income	2,091.9	3,972.8	4,672.6	5,123.5	4,592.7
+ Net Income — Continuing Ops	2,001.9	3,831.4	4,614.8	5,026.4	4,492.2
+ Net Income — Discontinued Ops	-4.6	23.0	0.0	0.0	0.0
+ Other Comprehensive Income	-314.4	-200.1	-100.0	-774.8	-812.2
Total Comprehensive Income	1,777.5	3,772.7	4,572.6	4,348.7	3,780.5
Net Income to Common	1,960.3	113.3	147.1	5,040.0	4,513.0
Minority Interest	131.6	3,859.5	4,525.5	83.5	79.7
Per Share
Basic EPS	19.30	38.14	44.97	50.09	44.87
Diluted EPS	19.30	38.14	44.97	50.09	44.87
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	-7.0	29.2	0.0	0.0	0.0
+ Tax — Discontinued Operations	-2.4	6.2	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-100.0	-774.8	-812.2
+ Items NOT to be Reclassified to P&L	-16.0	-54.3	-0.5	-32.9	-3.5
+ Tax on Items NOT to be Reclassified	—	—	0.0	13.5	16.0
+ Tax on Items NOT to be Reclassified — alt tag	0.3	-6.1	—	—	—
+ Items to be Reclassified to P&L	-298.1	-151.9	-99.5	-728.4	-792.7
Comprehensive Income — Owners of Parent	1,645.9	3,659.4	146.9	4,267.3	3,707.6
Comprehensive Income — Non-controlling Interests	131.6	113.3	4,425.7	81.4	72.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	19.35	37.91	44.97	50.09	44.87
Diluted EPS — Continuing Operations	19.35	37.91	44.97	50.09	44.87
Basic EPS — Discontinued Operations	-0.05	0.23	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	-0.05	0.23	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	10,927.3	13,319.2	16,903.5	19,855.8	20,848.8
Gross Margin %	63.39	68.14	72.73	73.14	72.92
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	3,193.9	4,823.1	6,246.3	7,137.7	6,541.9
− Exceptional Items (reconciliation)	-604.2	-14.2	-219.6	-516.6	-534.8
Net Income Adj (tax-effected)	2,559.0	3,984.1	4,840.8	5,515.7	4,992.6
EPS Adj	23.61	38.25	46.59	53.92	48.78
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	101.2	100.6	100.6	100.6	99.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.